To the Editor We read with great interest the article by Santos et al.1 We would like to congratulate the authors on this important study. A randomized clinical trial with few crossovers during the study period is challenging to perform in this setting and deserves respect. We have the following comments and questions to the authors.
We believe that this trial supports the most recent guidelines by the American and European colorectal societies, which encourage individualized decisions on elective surgery.4,5 As in previous trials, the lack of a sham procedure in the control group led most certainly to an overestimation of the effect size. Expectancy regarding sigmoid resection appears to be safe. Mainly patients with frequent recurrences impairing their quality of life should be candidates for resection because they probably benefit the most. In our opinion, the present trial does not support elective sigmoid resections in patients with persistent pain owing to the low number of inclusions in this group.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Schultz JK, Azhar N, Buchwald P. Comments and Concerns on the LASER Trial. JAMA Surg. 2021;156(10):984–985. doi:10.1001/jamasurg.2021.2247
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.